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ABSTRACT 
DNA immunization is a rapidly developing vaccine platform for infectious diseases, cancer 
and allergies. The efficiency of DNA vaccination is largely determined by the efficiency of 
delivery and subsequent expression of genes encoding microbial and tumor antigens or 
allergens in the cells of vaccine recipients. DNA immunogens are generally administered by 
intramuscular or intradermal injections, followed by electroporation to enhance the DNA 
uptake into the cells. An intense debate on the pros and cons of different routes of DNA 
delivery is still ongoing.  
The aim of this work was to develop in vivo imaging applications for improvement of DNA 
immunization. The first aim was to optimize delivery techniques in order to increase the 
efficacy of in vivo delivery of DNA vaccines and subsequent immune response. Using model 
DNA immunogens encoding luciferase, and HIV-derived immunogens encoding protease 
(PR) and reverse transcriptase (RT), we defined the differences in the strength and type of 
immune responses induced by them when administered by intradermal or intramuscular 
injection routes followed by electroporation. Furthermore, we determined the extent to which 
the method of DNA delivery influences the immune response to Th1 and Th2 type 
immunogens, represented by plasmids encoding PR and RT of HIV-1. Finally, we developed 
imaging applications for the in vivo assessment of  the effector/lytic potential of the immune 
response in tumor and surrogate pathogen challenge models.   
We immunized mice with DNA immunogens mixed with a gene encoding a bioluminescent 
reporter. Bioluminescence imaging (BLI) served as a tool to monitor the expression of 
delivered reporter genes in vivo. By combining the readouts form BLI and immunoassays we 
defined a set of delivery parameters that led to the best immunization outcome in terms of 
both immunogen expression and subsequent immune response. After optimizing the delivery 
conditions we tested different immunization routes to determine the one that ensures maximal 
immunogenicity of DNA immunogen. Here we show that intradermal administration resulted 
in a significant enhancement of both cellular and humoral immune responses as compared to 
intramuscular delivery. This was evident regardless of the nature of the immunogen (Th1 vs. 
Th2). The kinetics of the loss of co-delivered reporter gene expression was found to correlate 
with the antigen-specific production of IFN-γ and IL-2 and could thus be used as in vivo 
correlate of the strength of specific immune responses. Thus, non-invasive imaging allowed 
to assess the  immunogenicity of DNA vaccines in vivo. Using the same parameters we 
developed a surrogate method that could assess effector memory responses. Finally, we 
applied BLI to study the growth of luciferase-labeled tumors in luciferase-immunized 
animals, which provided a functional measure of vaccine efficacy.  
Overall, the use of BLI allowed us to establish a methodology to increase the efficacy of 
delivery, define optimal regimens and test the effector capacity of the immune response 
induced by DNA vaccination. The application of this technique made it possible to 
significantly refine and reduce animal experimentation in gene vaccine development. 
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1 INTRODUCTION 
1.1 DNA VACCINES 
A DNA vaccine is described as a genetically engineered plasmid that codes for antigenic 
proteins under the control of an eukaryotic promoter, which when delivered in vivo directs 
expression of the encoded protein(s) (1). Although DNA vaccines are referred to as a 
relatively new vaccination vehicles, the inception of this strategy was commenced more than 
50 years ago during the conduction of tumorigenesis studies. Independently, two groups were 
able to show that introduction of tumor DNA derived from mice resulted in the development 
of tumors in the mice, in which it was injected (2, 3). However, it was not until the 1980s 
when the studies of in vivo expression of injected plasmid DNA really exploded (4). Studies 
proved the concept of in vivo activity in animal models: it was demonstrated that Hepatitis B 
Virus (HBV) DNA could induce hepatitis in chimpanzees (5) and that the synthesis of growth 
hormone can be triggered by the injection of its gene in rats (6). Even at this early stage some 
studies were able to show the induction of immune responses after DNA injection. Seeger et 
al. demonstrated that an intrahepatic injection of Ground Squirrel Hepatitis Virus genomic 
DNA elicited the production of specific antibodies against its antigen, which confirmed the 
activation of humoral immunity in these animals (7). 
Although many of these studies were able to validate the principle of in vivo expression of 
injected DNA, they frequently utilized special DNA preparations, including liposome 
encapsulation or calcium phosphate precipitation to improve cell transfection rates (8–10). 
Not long thereafter, researchers were able to show that the injection of a pure DNA plasmid 
was also capable of in vivo transfection and protein expression. Wolff et al. were among the 
first to manifest the phenomenon by administering a selection of reporter genes by 
intramuscular (IM) injection in mice and observing the gene products in transfected murine 
cells (11). 
The demonstration of efficacy of in vivo DNA transfection led to the initiation of a plethora 
of studies exploring DNA vaccination. Groups reported production of antibodies against 
Human Growth Hormone in mice following a genetic immunization with genes derived from 
Human Growth Hormone (12). The immunological protection from disease by DNA 
immunization is attributed to Ulmer et al. (13) for cell mediated immunity and Fynan et al. 
for humoral immunity (14). The former demonstrated protection against H7N7 influenza after 
administration of two doses of an H7-expressing DNA construct. The latter further elaborated 
on the role of different delivery routes in protection against influenza challenge. In these early 
stages of technological breakthrough many renowned international vaccine meetings featured 
presentations on the use of DNA vaccines against infectious diseases (13–15). 
Due to the promising results already acquired in small animal models, clinical trials were 
bound to soon ensue. Almost 20 years ago, the first phase I trial became a reality. Its purpose 
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was to evaluate the efficacy of a therapeutic/prophylactic DNA vaccine targeting human 
immunodeficiency virus type 1 (HIV-1) (16). The range of targets expanded rapidly as 
studies targeted other infectious agents such as influenza, hepatitis, human papillomavirus 
(HPV), and also cancer. DNA vaccines were safe and very well tolerated, but the overall 
results showed less immunogenicity in humans than had been expected from animal studies. 
Immunogenicity manifested by low CD8+ and CD4+ T-cell responses and low antibody titers 
was disappointing. Nevertheless, these studies served to show that DNA vaccines could 
safely be used to induce immune responses in humans (even though they were of suboptimal 
frequency). 
1.2 BENEFITS OF DNA VACCINES 
DNA vaccines feature several fundamental advantages that set them apart from the 
conventional vaccination platforms, such as protein, viral inactivated, or live attenuated viral 
vaccines. They are much safer than attenuated and inactivated vaccines, which may hold the 
risk of triggering an infection due to incomplete inactivation or poor attenuation of the virus. 
Existing reports have pointed out the risks associated with the latter, especially for 
debilitating diseases such as poliomyelitis, where the strain of poliovirus in the oral poliovirus 
vaccine had reverted to neurovirulence and caused vaccine-associated paralytic poliomyelitis 
in vaccinees or lead to emergence of vaccine-derived poliovirus strains (17, 18). 
The backbone of DNA vaccines are bacterial plasmids, which are relatively easy to design 
and produce even on a large scale. Additionally, they are relatively stable (19), which 
facilitates their production and distribution. Full-length genes are readily incorporated in 
DNA constructs, which allows for correct subsequent maturation, glycosylation and 
processing, potentially providing immunogenicity close to that of the native protein. 
Importantly, DNA plasmid vectors can be designed to express only the antigen of interest, 
while the vectors are designed to be non-immunogenic. This offers the benefit of using 
prime-boost regimens and avoiding the development of vector-specific immune response, as 
opposed to the situation with carriers of viral or bacterial origin (20).  
Furthermore, DNA plasmids possess an inherent adjuvanticity because of the incorporation of 
cytosine-phosphate-guanine oligonucleotide sequences (CpG), the so called CpG motives. 
Most DNA immunogens contain bacterial antibiotic resistance genes as well as bacterial 
regulatory sequences needed for plasmid propagation in E. coli. This creates multiple 
stretches of unmethylated DNA. Toll-like receptor 9 (TLR9), a receptor found on the surface 
antigen presenting cells (APCs), recognizes CpGs (21) and may drive the priming and 
differentiation of cytotoxic T lymphocytes (CTLs) by induction of pro-inflammatory 
cytokines, such as type I interferon and IL-12 (22). The presence of CpG motifs is not 
absolutely required for the induction of immune responses, however, they are undoubtedly 
involved in the induction of the immune response (22).   
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1.3 IMMUNE ACTIVATION BY DNA 
The capacity of DNA vaccines to engage pattern recognition receptors (PRR) such as TLR9 
has been  shown to be significant in prime, but not in prime-boost immunization schedules 
(23). Although many studies have investigated and confirmed the connection between TLR9 
activation and induction of DNA-specific responses, TLR9 knockout models have shown that 
the receptor is not essential for DNA vaccines to work (22, 24), which implies the 
involvement of other DNA sensors that contribute to the immunogenicity (Fig. 1).  
The first of what turned out to be a long array of cytosolic DNA receptors was identified in 
2007 and called DNA-dependent activator of interferon regulatory factors (DAI) (25). 
Takaoka et al. showed that DAI was capable of upregulating the expression of type I IFNs 
via NF-κB and IRF3 and to bind to DNA. Two years later, in 2009 another pathway in 
response to DNA was discovered, which was unusual because of the involvement of RIG-I 
and MAVS (26, 27). RNA polymerase III (RNA Pol III) was shown to be able to transcribe 
AT-rich dsDNA in RNA, which subsequently triggers RIG-I leading to production of IFN-β. 
However, there were still a multitude of DNA responses that could not be accounted for, 
especially provided that RNA Pol III-RIG-I pathway could only explain the detection of AT-
rich stretches of DNA and DAI was only known to act in a cell-specific manner (28). This 
suggested that additional mechanisms of DNA sensing existed that remained to be elucidated. 
In 2008, an important event in the field occurred – several groups in parallel identified the 
existence of a signaling adaptor protein, STING (29–32). It was shown to be important in 
IFN-β response to DNA and in Sting-knockout mice responses to infection by DNA viruses 
were severely abrogated (33). Although all of the mechanisms by which STING activates 
NF-κB have not yet been determined, a lot is already known, such as its role in the response 
to viral and bacterial pathogens, self-DNA in autoimmune disorders and mediation of 
immune activation by DNA-based adjuvants (34). The function of STING in recognition of 
bacterial second messenger molecules such as cyclic dinucleotide diguanylate 
monophosphate (c-di-GMP) and recently of the mammalian second messenger cyclic-GMP-
AMP (cGAMP) has been of high interest. In addition to its adaptor functions in IFN response 
to DNA, STING was shown to directly bind c-di-GMP serving as a direct sensor of cyclic 
dinucleotides (35). Cyclic dinucleotides have recently emerged as effective vaccine adjuvants 
and immunotherapeutics and the mechanisms by which they are sensed by the innate immune 
system has been a heavily researched topic (36). Recent work has established an association 
between STING and both protective and debilitating responses in vivo. Some studies 
exploring its role in cancer immunotherapy have shown that, in mouse tumor models, 
activation of STING in dendritic cells (DCs) by the recognition of tumor cell DNA can 
induce protective IFN-β responses that in turn enable DCs to present tumor associated 
antigen to CD8+ T cells (37, 38). Inversely, STING has been implicated in exacerbation of a 
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condition where defective DNase activity causes excessive accumulation of self-DNA and 
STING-mediated inflammatory responses (39).  
The discovery of STING stimulated intense research that led to a more detailed description of 
this signaling pathway. In 2013, Wu et al. identified a factor called cGAMP, which was 
shown to bind STING and activate IRF3 (40). This novel pathway, upstream of STING, 
involved cGAMP synthase (cGAS), which is activated upon DNA binding, causing its 
conformation to change in turn allowing access of nucleotide substrates to its active site, 
followed by cGAMP synthesis (41). DNA sensing by cGAS has been confirmed in cGAS 
knockout mice, which were not able to induce IFN responses to DNA or infection by DNA 
viruses (vaccinia, HSV-1) and were significantly more susceptible to lethal challenge by 
HSV-1 as compared to wild type mice (42, 43). cGAS has also been shown to play a role in 
sensing of HIV-1 as infected lymphocytes are known to produce cGAMP and the virus 
induced IFN response was cGAS-dependent (44). 
 
Figure 1. Timeline of discovery of cytosolic DNA sensors and signaling molecules. DNA 
sensors are colored in red, signaling molecules in orange and RNA sensors – in purple. 
Inspired by Dempsey et al. (45) 
1.4 IMMUNE RESPONSES INDUCED BY DNA VACCINES 
Historically, one of the most significant hindrances in the development of DNA vaccines has 
been the inability to reproduce the results of successful protective immunity, demonstrated in 
small animal models, in larger animals (46–48). However, recent developments such as 
codon optimization, gene design and the use of adjuvants have brought DNA vaccines back 
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into the spotlight. When combined, optimization strategies have been shown to enhance both 
cellular (49) and antibody (50) responses. Importantly, this has been reported in rodents as 
well as in larger animal models. These results go to show that a better understanding of the 
way immune responses are elicited by DNA vaccines is key for our ability to enhance them. 
1.4.1 Cellular responses 
Cellular responses following DNA vaccine delivery mimic the sequence of events seen after 
infection by а live virus. In either case the end result is the synthesis of an antigen within the 
host cell followed by its processing, loading, and surface presentation of the processed 
antigen in complex with MHC molecules. There are a few distinct ways that the vaccine 
antigen can be acquired, processed and presented, which in turn determine the overall 
resulting immune response. Firstly, immune cells can be primed by somatic cells that have 
been transfected and made to express the vaccine-encoded antigen. Upon transfection, 
somatic cells process the antigen via the endogenous pathway and subsequently present it 
loaded on MHC I molecules to antigen-specific CD8+ T cells. Lacking any means of co-
stimulation, somatic cells are unable to prime naïve CD8+ T cells (51, 52); however, 
maintained expression of vaccine antigen can still provide the antigen and augment the 
response after DNA immunization (53). APCs can acquire exogenous antigen that has been 
secreted by transfected somatic cells or from phagocytosing apoptotic cells. Secondly, APCs 
present at the site of immunization or in draining lymph node cells (LN) can be directly 
transfected by the vaccine immunogen, process and present it on MHC I molecules. Those 
APCs possess co-stimulatory signals and can therefore prime naïve CD8+ T cells and induce 
CTLs (54, 55). They can also prime CD4+ T helper cells via MHC II presentation (56). There 
are also reports of endogenous antigen entering the exogenous processing pathway and being 
presented on MHC II molecules (1, 56). Another way of acquiring antigen is the recycling of 
antigen from dying APCs. During this process pre-loaded MHC I molecules can be processed 
and the antigen presented on MHC II molecules (57) or cross-dressed (58) and directly 
presented on the surface of other phagocytizing APCs. All of the latter pathways result in the 
antigen being normally processed and presented on MHC II molecules. However, APCs are 
special in their ability to cross-present, which translates into antigen escaping from the 
endosome into the cytosol, where it goes through the endogenous antigen processing pathway 
and is finally presented on MHC I molecules (59, 60). Due to these processes exogenous 
antigens acquired by APCs can theoretically serve for priming both naïve CD4+ T helper (Th) 
cells and naïve CD8+ T cells or CTLs by utilizing the appropriate presentation pathway. 
1.4.2 Antibody-dependent cellular cytotoxicity 
A hybrid way of cytolysis of antigen-expressing cells is mediated by effector cells in the 
presence of antigen-specific IgG. This phenomenon was first described in the mid-1960s by 
Erna Möller, who showed that incubation of mouse tumor cells with serum from rabbits 
previously immunized with these cells, followed by incubation with lymphocytes from non-
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immunized mice resulted in elimination of the tumor cells (61). It was characterized as 
“serum-induced aggregation” between the tumor and effector cells, however, later on it 
became to be known as “antibody-dependent lymphocyte-mediated cytotoxicity” (62) and 
finally as antibody-dependent cell-mediated cytotoxicity (ADCC) that is the term most 
frequently used today. The main components in ADCC are target cells, antibodies and 
effector cells and this mechanism is known for its capacity to lyse tumor and pathogen-
infected cells. A simplified summary of the process can be defined as the ability of effector 
cells expressing Fc receptors to lyse cells bearing surface antigens complexed with 
antibodies. 
The understanding of ADCC depends on the elaborate knowledge of the key players 
involved. Although there have been diverse evidence of the participating effector cells, recent 
data show that their unifying characteristics can be summarized as granular leukocytes 
expressing FC receptors. It is important to state that both mononuclear (NK cells, 
macrophages, γδ T cells) and polymorphonuclear (neutrophils, basophils, eosinophils) 
leukocytes can carry out ADCC activity (63). A large proportion of studies classify it either 
NK- or PBMC-mediated, which leads to bias and an unintentional undermining of 
polymorphonuclear leukocytes in this immunological context. 
IgG-dependent ADCC involves the engagement of three types of Fcγ receptors: FcγRIIIA 
(CD16), FcγRII (CD32) and FcγRI (CD64), with CD16 being the one that is most often 
mediating the binding process as it is expressed on NK cells (64, 65). IgA-dependent ADCC 
utilizing FcαR (CD89), which is most abundant on the surface of monocytes, has also been 
reported (66).  
Initiation of ADCC requires interaction between the antibody-antigen complex and the Fc 
receptor on the effector cell. After binding to its cognate antigen, the Fc region antibody 
undergoes a conformational change that increases its affinity for a specific Fc receptor on 
effector cells. The affinity to different Fc receptor is heavily affected by the degree of 
glycosylation (67, 68). Since the main body of data describes ADDC activity after cross-
linking between FcγRIIIA on NK cells and Fc part of IgGs, the best described downstream 
pathway is the one taking place in NK cells. The established model postulates that after cross-
linking the gamma subunit of the FcγRIIIA receptor, containing tyrosine-based activation 
motifs (ITAMS), becomes phosphorylated by spleen tyrosine kinase (Syk). Binding of Syk 
activates the three main pathways involved in ADCC, which in turn can activate three 
mechanisms of killing: perforin/granzyme assisted pathway, FAS-ligand (FAS-L) pathway, 
and reactive oxygen intermediates/species (ROI/ROS) pathway (69). The perforin/granzyme 
pathway is the one having attracted the most attention and as a result is the best described. 
After FcγRIIIA cross-linking signaling pathways lead to increased calcium content, 
intracellular microtubule reorganization and polarization and release of cytotoxic 
perforin/granzyme granules (70). Killing of target cells occurs through the well-coordinated 
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actions of both perforin and granzyme B. Perforin by itself is capable of mediating cell lysis 
but not apoptosis, which requires granzyme B. It penetrates the cell, activating caspases that 
trigger DNA fragmentation or initiating a sequence of events that results in the release of 
mitochondrial contents that either enhance caspase activation or induce caspase-independent 
apoptosis (71). The FAS-L pathway is significantly less studied and evidence for it is also 
less substantial. It attributes killing of target cells to a combination of granule secretion and 
transcriptional activation of FAS-L, which enables NK cells to kill cells expressing FAS 
receptors (72). The last mechanism of killing, by ROI/ROS is still very controversial. It is 
based on the fact that phagocytic cells produce ROS in response to antigen opsonization. 
ROS such as hydrogen peroxide, superoxide and other free radicals are released and in turn 
damage the opsonized entity (73). 
1.4.3 Antibody responses 
The capacity of DNA vaccines to induce antibody responses are usually less potent than the 
capacity to elicit the cellular immune responses (4). A possible explanation for this is the 
endogenous nature of the encoded antigens. The intracellular localization of the antigen 
pushes its subsequent processing in the direction of the MHC I pathway. Live virus (74) and 
protein subunit (75) vaccines have been reported to induce a higher magnitude of antibody 
responses compared to their DNA counterparts. By definition, the induction of humoral 
responses requires antigen to be recognized by the B cell receptor, or be processed through 
the MHC II pathway, which is not possible unless the source of antigen is exogenous. Thus, a 
likely bottleneck effect might be created by the lack of extracellular antigen, which in turn 
leads to insufficient activation of this arm of the immune system. This explanation is 
supported by the fact that DNA vaccines encoding secreted immunogens result in much more 
potent humoral responses than those encoding intracellular ones (76–78). It has also been 
reported that the induction of vaccine-specific CTLs has resulted in enhancement of humoral 
responses (79) suggesting the existence of a synergistic activation of both compartments of 
the adaptive immune response. Induction of antigen-specific Th and CD8+ T cells after DNA 
vaccination has also been observed in cases where protective antibody responses were 
involved (80). To reach maximum potency antibody responses take between 4 and 12 weeks 
starting from DNA vaccine administration; the antibodies raised are durable (81), have good 
neutralizing capacity and high avidity (1). The most frequently observed antibody subtypes 
after DNA immunization are IgA and IgG and the subclass, which is usually heavily 
influenced by the overall Th1 polarization caused by DNA vaccines, may result in higher 
abundance of IgG2a/b than IgG1 (82). Typically, immunization with DNA constructs 
encoding secreted antigen results in the generation of IgG1 antibodies (78), which is also an 
effect observed after using delivery modalities, such as the gene gun or biojector (82).  
Importantly, the route of DNA administration and the way it is delivered can heavily 
influence the immune response, which may have to deal with the type and location of the cell 
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that is transfected and in turn expresses the antigen. In mice, the intramuscular (IM) route of 
DNA administration resulted in significant antigen-specific antibody responses, which were 
not directly depending on expression of the antigen at the site of immunization. In 
comparison, when DNA was administered via the intradermal (ID) route by gene gun, 
humoral responses were of lower magnitude and seemed to require antigen expression at the 
site of delivery. Thus, it appeared that in ID immunization skin has a vital role in the 
generation of antibody responses; however, in IM vaccination muscle cells did not provide 
essential input (83). 
1.5 DNA VACCINES FOR CANCER IMMUNOTHERAPY 
Cancer immunotherapy recruiting the immune system of the host to eliminate tumors and 
preventing their reoccurrence has been generating significant attention in recent years. 
Despite the advantages of DNA vaccines and their ability to induce potent cellular and 
humoral immune responses, they have had only limited success in fighting cancer. Intense 
optimization has managed to significantly enhance the immunological efficiency of DNA 
vaccines, contributing to the ultimate goal of precluding foreign agents such as viruses from 
causing disease (84). However, the oncogenic etiology of most tumors stems from 
uninfected, normal tissue expressing antigens, which are either recognized as self, resulting in 
tolerance and even if modified are still weak immunogens unable to drive effective immune 
responses. Additionally, such autoimmune reactivities are tightly controlled by 
CD4+CD25+FoxP3+ regulatory T cells, which can suppress such lymphocyte functionality 
(85). Another hindrance for an effective response is the fact that cytotoxic lymphocytes that 
recognize an aberrant cancer antigen can become anergic due to the lack of expression of 
costimulatory molecules, again resulting in immunological tolerance. Finally, tumors are sites 
of increased mutagenesis, which often results in the loss of immunodominant epitopes that 
can prevent the immune system from mounting a tumor-specific response thus further 
impeding the effect of vaccines that target them (85). Despite this, recent clinical trials have 
been using a personalized approach of inducing T cell response against neoantigens unique 
for the patient undergoing treatment. These studies used computational methods to predict 
arising mutations and deliver a vaccine that is often combined with additional therapy such as 
PD-1 blocking. The results in vaccination against melanoma using this approach have shown 
significantly reduced metastatic events and tumor progression, which ultimately resulted in 
tumor control and sustained survival in these patients (86, 87). 
One of the absolute prerequisites for developing a successful DNA vaccine is the 
identification of tumor-specific antigens tumor-associated antigens (TAAs) (88). The first 
human TAAs were discovered about 20 years ago; however, there was a series of preceding 
events that ultimately lead to this initial stage of discovery. For a period of 20 years starting 
from the 1940s the scientists worked on coining the basic idea that tumors induced by 
oncogenic viruses can be rejected in mice following recognition of viral antigens by the 
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immune system (89). As a consequence of this, it was shown that chemically-induced tumors, 
could also be recognized by the immune system and mice were able to reject the same tumor 
cells upon repeated challenge (90). Contrary to this, in the mid-1970s it was observed that 
when tumors developed spontaneously in mice there was no evidence of the immunological 
response being able to control their growth (91). During the same period Boon et al. laid the 
foundation of tumor-specific antigen discovery with their work in mice showing that immune 
tolerance to mouse teratocarcinoma could be broken when they induced mutations in a 
tumorigenic cell line producing so the called “tum-” variants not capable of forming tumors. 
When syngeneic mice were injected with these cells, an immune response was mounted 
against them (92). Interestingly, injecting teratocarcinoma cells in mice which had earlier 
received “tum-” cell line variants prevented any tumor development. This served as evidence 
that identification of the mechanism of tumor rejection in humans can translate into a vaccine, 
which could induce the immune response inhibit tumor formation in patients (93, 94). 
In the early 1990s, van der Bruggen et al. used the approach that helped to discover the 
existence of tumor specific antigens in mice and described the first TAA to be recognized by 
T cells, called melanoma antigen family A, 1 (MAGEA1). Multiple classes of self TAAs 
have been identified since this discovery (88). Knowledge of TAAs has been successfully 
applied in the development of licensed veterinary DNA vaccines (43). However, low 
immunogenicity still remains the main barrier for the progress of such vaccines in humans. 
The few exceptions to that are antigens derived from oncogenic viruses such as HPV, which 
served as a basis for the prophylactic vaccine against cervical cancer (95). Very recent 
attempts have shown promising results by utilizing novel immunization platforms to induce 
potent responses against a germline tumor antigen, Wilm’s tumor gene 1 (WT1), which is 
overexpressed in many human malignancies. Walters et al. have managed to significantly 
enhance anti-tumor immune responses by using synthetic micro-consensus DNA vaccine 
approach to break tolerance in non-human primates (96). The synthetic DNA encodes a 
consensus protein sequence that was generated by using amino acid sequences of the target 
protein from various species, but without altering protein structure. Immunization with 
electroporation (EP) elicited immune responses against native WT1 peptides and was capable 
of slowing tumor growth. This is just a singular example of a way in which antigen 
optimization can potentiate immune responses in an environment, where their induction is a 
significant issue. Similar attempts have been a continuous research trait in DNA vaccine 
targeting prevention and treatment of viral infection by highly variable pathogens such as 
HIV-1 and some other viral antigens. Although eliciting immune responses against foreign 
antigens is theoretically simpler than immune recruitment against self, it takes deep 
understanding of the functions of the cellular and humoral compartments of the immune 
system to successfully stimulate them. 
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1.6 DELIVERY OF DNA VACCINES 
The new generation of DNA vaccines that are currently being developed have brought about 
significant improvements and have successfully turned the spotlight back to this vaccine 
modality. These new DNA vaccines are capable of generating enhanced cellular and humoral 
responses in small, as well large animal models including primates (97). 
Low immunogenicity of DNA vaccines has been to large extent attributed to inefficient 
delivery of plasmids, their poor uptake by cells which led to low level of expression of 
encoded immunogens. Therefore, much effort has been dedicated to devising new methods of 
delivering DNA vaccines that can maximize the efficacy of in vivo transfection. The research 
was focused on optimization of a number of parameters, such as immunogen design, vaccine 
formulation, and, importantly, the delivery of DNA into the targeted anatomical 
location/target tissues (98). 
1.7 ELECTROPORATION 
EP is a method of delivery of charged (macro)molecules (Fig. 2). Substantial improvements 
in EP have been achieved during the past three decades allowing for its clinical integration in 
life-saving procedures such as electrochemotherapy (99). In application to DNA, it utilizes 
pulses of electrical current to achieve transfection of the cells. The electrotransfer of DNA 
and genes in varying cell types or electrogenetherapy (100) is now widely researched with 
multiple ongoing clinical trials, but is yet to be established as a standard procedure in the 
clinic (101). Clinical studies have shown this modality of gene delivery to be safe in patients. 
A phase I clinical trial was completed confirming the safety of EP-assisted transfection of IL-
12 in patients with metastatic melanoma (102). In case of DNA vaccination, it greatly 
enhances the rate of in vivo transfection of the cells at the site of vaccine administration, and  
hence, vaccine immunogenicity (103). 
1.7.1 Electric field and DNA-membrane interactions 
The exact mechanism by which this technique increases the efficacy of DNA vaccination has 
not been elucidated, however, there are several theories supported by experimental data. 
Early single-cell experiments have allowed us to look into the mechanics of molecule 
electrotransfer. Size is known to be a limiting factor for entry into cells and small molecules 
have almost unrestricted mobility under the conditions of electrotransfer (104). They can 
cross the plasma membrane of electropermeabilized cells during the application of electrical 
pulses or in the interval of a few minutes following it (105). However, when the 
electrotransfer of larger molecules such as DNA is considered, the process seems to follow a 
more elaborate sequence of events. DNA must first approach, insert itself into and translocate 
across the cell membrane, then migrate through the cytosol towards the nucleus and finally 
cross the nuclear membrane (106–109). The electrotransfer of DNA is only possible when 
DNA is present prior to the introduction of the electric field.  Experiments have shown that  if  
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Figure 2. Mechanism of DNA electrotransfer. When an electric field is applied (1) the 
plasma membrane is permeabilized and DNA is dragged into the cell membrane proximal to 
the cathode by electrophoretic forces (2). DNA-membrane interactions occur (3), which 
causes the formation of aggregates and transient accumulation. Following electric field 
application and membrane resealing (4) DNA is internalized mainly by endocytosis. During 
the intracellular transport DNA passes through different endosomal compartments (5). The 
successful migration of DNA depends on interactions with cellular motor or adapter proteins. 
In order to be expressed DNA must then escape the endosomal compartment in proximity to 
the nucleus (6). Finally, DNA must cross the nuclear envelope (7) and be processed yielding 
proteins that are released into the cytoplasm (8). The figure was adapted from (110). 
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DNA is added even 2 seconds after EP, transfection either does not occur or is insignificant 
(111). Although there are contrasting hypotheses on the matter, some studies have suggested 
that the permeable membrane structures formed by the electric field are very short-lived and 
only exist while the electric field lasts (101, 109). Moreover, the interaction between DNA 
and the cell membrane requires electrophoresis to overcome the negative charge on both, 
which would otherwise cause a repulsion. Importantly (and confirming the importance of 
electrophoresis), adding agents that reduce electrophoretic mobility (cations) causes a sharp 
drop in the transfection efficacy (112). This observation has been experimentally confirmed 
for multiple tissue types both in vitro and in vivo (113, 114).  
The importance of electrophoretic mobility for induction of DNA-cell membrane interaction 
is further emphasized by the asymmetric nature of DNA migration under in the electric field. 
Visualizations have shown that fluorescently labeled DNA interacts with the membrane only 
on the side facing the cathode. When an electric field is applied DNA moves to the anode 
permeabilizing any cells in its way and forms DNA-membrane complexes. These interactions 
are directly dependent on the polarity of the electric field (115). However, if a bipolar electric 
field (alternating current) is applied, the interactions described above will occur on both sides 
of any cell within the electric field, which will improve the uptake of DNA (116). Complexes 
between the cell membrane and DNA are formed in two distinct ways: the latter can either 
become anchored at one side or it can become inserted within the membrane (117). The EP 
parameters determine the nature of the complexes that are formed (115), however the 
biophysical structure and significance of the different DNA-membrane complexes remains to 
be elucidated.  
1.7.2 DNA internalization 
The actual process, by which internalization occurs, and the activities of the cell during and 
after the transfer are not fully understood (118). There are several hypothetic models, but they 
fail to explain the whole process in its complexity. 
One of the prevailing theories relies on the formation of electropores. This was the first of the 
proposed mechanisms which suggested that plasmids enter the cell via stable macropores on 
the cell membrane (119, 120). Application of electric field was postulated to alter the 
membrane potential not resulting in the membrane rupture, but rather in the generation of 
hundreds of pores of size varying between 1 and 400 nm. The model predicted that this 
process creates a sufficient number pores large enough to allow plasmids to enter cells even 
in their circular conformation. The pores were proposed to maintain an open state for the 
entire duration of the EP procedure (121). 
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Another model also revolves around the existence of electropores, however, the entry of 
DNA into the cell is attributed mainly to the electrophoretic forces, which aggregate the 
plasmids on the cell surface and then push them through the pores (112, 122). The electric 
field is proposed not to be able to penetrate the initially intact membrane. However, upon 
pore formation it is able to cross the membrane through them (123). In fact, the electric field 
is concentrated on the pores and even if their size of about 1 nm is insufficient for the plasmid 
to pass, the DNA enters, driven by the electrophoretic pressure on the permeabilized 
membrane (124). This mechanical interaction is suggested to be able to adjust the size of the 
pores and also prevent their closure if the plasmid is partially through them, even after the 
electric field has been discontinued (125). 
Even though electropermeabilization of the cell membrane remains the stepping stone for 
successful gene electrotransfer, internalization through pores has become more and more 
difficult to accept due to the fundamental differences between small molecules and DNA, 
which tends to exist as large complexes before entering the cell. A third model proposes an 
entirely different pathway for DNA internalization. At its foundation is the phenomenon that 
application of an electric field could encapsulate DNA inside giant unilamellar vesicles (126). 
The model suggests an endocytosis-like internalization of DNA via the formation of vesicles. 
This endocytic uptake of DNA was first theorized in the early 1990s (112, 127), however it 
received little attention because the main focus at the time was on the electropore theories, 
which were seen as much more plausible considering the well described mobility of small 
molecules across the membrane. This is why endocytic pathways for internalization have 
been recently gaining more and more attention. 
1.7.3 Intracellular DNA transport 
The cell cytoplasm consists of an intricate and dense network of microfilaments, 
microtubules and intermediate filaments (forming the cytoskeleton) in addition to various 
organelles and proteins. The tightness of this molecular mesh makes diffusion of large DNA 
complexes a very unlikely event. While the mobility of molecules of size about 700 Da is 
only 4 times lower in the cytoplasm as compared to water, increased size quickly renders 
larger molecules immobile (128). When plasmid DNA is microinjected into the cytoplasm or 
nucleus its mobility is shown to be negligible (129, 130). DNA fragments larger than 2 kb are 
unable to diffuse through the cytoplasm (131). In the post-EP cellular environment, DNA 
takes much longer to reach the nucleus compared to small molecules (few hours vs few 
minutes) (117). Expression of the transgene is already observed 3 h after EP and if ATP is 
depleted 2 h after EP, gene expression is significantly reduced with no effect on cell viability 
(132). Very similar transgene expression kinetics have been observed after transfection, 
which was not assisted by EP (133).  These data suggest that intracellular trafficking of DNA 
depends on the ATP levels, i.e. is not purely mechanical, but is driven by the cellular 
machinery. 
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According to the existing theories of DNA internalization, it can either enter the cell through 
electropores propelled by electrophoresis, or is shuttled in endosomal vesicles. In the first 
case, DNA would rapidly form complexes with DNA-binding proteins and intracellular 
polycations (134). This will neutralize its negative charge, make DNA more compact and 
also protect it from degradation (135). DNA is not known to bind to any motor proteins, so 
the only scenario of active transport of these complexes is if some of the DNA-binding 
proteins or polycations serve as adaptors and anchor it to the cellular motors. However, if 
DNA entered the cell in vesicle, it would already be equipped with the necessary proteins to 
attach to these motors (136) as endosomes can take advantage of the cellular machinery and 
be transported freely through the cytoplasm and reach the nucleus. 
Colocalization studies in electroporated CHO cells have shown that DNA can be found in 
significant amounts in vesicles expressing Rab5 (early endosomes), Rab11 (recycling 
endosomes), Rab9 (late endosomes) and Lamp1 (lysosomes) (137). Rosazza et al. also found 
that in the early stages after EP most of the DNA was within Rab11 and Rab9 vesicles, 
whereas 2 h after that it was encapsulated by Lamp1 lysosomes (138). This shows that DNA 
trafficking essentially follows classical intracellular transport pathways. Understanding 
intracellular DNA trafficking is crucial for optimization of its delivery and subsequent 
expression. The knowledge that DNA complexes undergo lysosomal degradation prompted 
efforts to inhibit this process, which has actually been shown to improve its expression (139, 
140). A different approach could consist of using nanosecond electric pulses which would 
only permeabilize the internal membranes, and not the cell or nuclear membranes (141). This 
would help to release DNA at the endosomal stage, delivering it closer to the nucleus. These 
and similar strategies and their combinations can tremendously improve the process of in vivo 
transfection. 
1.7.4 Crossing the nuclear membrane 
The nuclear membrane is the last hurdle that internalized DNA needs to overcome before 
gene expression can be initiated. Localization studies have shown that even as late as 24 
hours after EP, when transgenes are already being translated, most of the electrotransferred 
plasmid is still in the perinuclear region (117). Only a very small fraction of the plasmid is 
able to cross the nuclear membrane. This hindrance is due to the large size of the DNA 
molecule. Molecules up to 40 kDa can easily diffuse through the nuclear envelope; however, 
transport of the plasmid, which a molecular mass of 1 MDa or more (1 kb = 0.66 MDa) 
requires a DNA nuclear targeting signal (142). In the absence of a targeting signal, DNA can 
also be imported into the nucleus during mitotic destabilization. Increased EP-assisted 
transfection rates have been documented in dividing as opposed to quiescent cells (143); 
however in some of those reports the plasmids did contain targeting sequences, which could 
drive the nuclear import (144). Thus, it still remains unclear how plasmids cross the nuclear 
membrane. 
  
 21 
 
1.7.5 Post-EP tissue traumatization 
Electropermeabilization of cells in vivo can be a source of significant disturbance of tissue 
homeostasis. Several direct consequences of applying electric fields are currently known. EP 
has been shown to result in the induction of high levels of ROS, which could be due to 
mitochondrial membrane instability and might negatively affect overall cell viability (145, 
146). To remedy this deleterious effect, antioxidants have been administered simultaneously 
with or before EP. In a study that investigated this phenomenon plasmid DNA was mixed 
with the antioxidant tempol and then electroporated into skeletal muscle. The authors 
reported a 40% increase in the transfection rate compared to the tempol untreated controls 
(147). Thus, diminishing of traumatization enhanced the expression, but not necessarily the 
subsequent immune response. 
Another side-effect of the electric pulses traveling through tissue is the generation of heat. 
Some EP protocols can significantly raise the local temperature and damage or even 
denaturate tissue (148). Lackovic et al. performed an in depth analysis of how different 
parameters of EP affect heat generation and distribution during pulse delivery. They found 
that the negative effects of the procedure can be minimized by using shorter pulses with small 
amplitude (148). 
The effect of electrical pulses on the blood flow is also a concern, even more so, for 
intravenous DNA delivery (149). A study investigated the effects of varying pH values in the 
post-EP tissue environment and discovered that when hyaluronidase, used to increase DNA 
uptake (150), is added to plasmid DNA, the electric current increases causing a strong shift in 
pH and significant tissue damage (151). 
The effect of electrical pulses on the blood flow is also a concern especially if DNA is 
delivered intravenously, as is required for systemic expression of the immunogen(s). A study 
done in skeletal muscles showed that EP results in a short-term reduction of perfusion (152). 
Another experiment indicated that electric pulses affect the subcutaneous vasculature. The 
authors showed that DNA was sensitive to vascular lock (i.e. the ability of blood to move 
through the vasculature) and constriction of the blood vessels significantly perturbed the 
movement of DNA through the vascular walls (153). 
Importantly, tissue damage inferred by the electric pulses leads to local inflammation, serving 
as a danger signal and recruiting macrophages, DCs, and lymphocytes (154, 155). This APC-
attracting effect has been observed in multiple animal models and is known to occur 
independently of plasmid delivery (156). A detailed study of skeletal muscle EP in mice 
showed that after application of ten 20-ms-long, 175 V/cm pulses morphological changes 
were readily observable after 3 h and lasted for up to 5 days. Infiltration of inflammatory cells 
coincided with observable tissue traumatization and mainly consisted of CD11c+ DCs. The 
study showed that 3 h post-EP there was no migration of lymphocytes to the site, however, 4 
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days after EP CD4+ T cells were detectable in moderate amounts, but CD8+ T cells presence 
was modest. APC infiltration also overlapped with a significant increase in the levels of TNF-
α and IL-1β, which are pro-inflammatory cytokines recognized as danger signals (156). A 
very similar adjuvant effect of electrical pulses has been demonstrated after intradermal EP-
assisted delivery of plasmids in macaques (157). The response to this sterile inflammation 
was driven by M2 macrophages and promoted tissue repair, which involved CD4+ T cells 
(133). 
1.7.6 In vivo application of electroporation 
The first studies that applied this method in vivo were conducted in the late 1990s. They 
evaluated the use of EP for in vivo delivery of transgenes in rat livers (158) and rat brain 
tumors (159). Those early studies successfully demonstrated the ability of EP to mediate gene 
transfer and expression. Additional experiments demonstrated that a huge enhancement of 
transfection efficiency: the rates of transgene expression were from 100 to 1000 fold higher 
in both muscle and skin as compared to the injection of DNA without EP (160–162). The 
efficacy of gene electrotransfer has been demonstrated in various tissue types with 
prophylactic and therapeutic applications targeting infectious diseases, cancer therapy, 
metabolic disorders and vaccines (163). 
In vivo plasmid DNA electrotransfer in humans is currently one of the most efficient non-
viral methods of gene delivery. Studies have shown it to be superior to the gene gun (164), 
liposomes (165), sonoporation (166) and the use of cationic lipids (167). The resulting gene 
expression is transient but can vary from a few weeks (168) to several months (169) with a 
possibility for repeated transfection capable of reproducing similar levels of expression. 
Adaptation of the EP procedure now allows the delivery of a gene(s) of interest in various 
target tissues such as skin, skeletal muscle, liver, kidneys, brain, heart, tumor and eyes 
without inflicting significant damage (170, 171). 
Some of the initial EP mediated vaccination studies aimed at assessing the expression of 
DNA-encoded antigens and their immunogenic potential. Primary targets of these studies 
were various HBV proteins and HIV-1 gag. Results showed that electrotransfer of these DNA 
constructs into muscle induced a significant increase in humoral response against HBV (172) 
and cellular immune responses against HIV-1 (173) proteins. Recently, many more pathogens 
have been added to the list of success stories, which EP has contributed to. The use of EP has 
enhanced immune responses against infectious agents such as: influenza (174–177), HIV 
(178), HCV, HPV and many others. Enhanced immunogenicity has also been demonstrated 
after delivery of DNA vaccines encoding antigens from numerous parasitic and bacterial 
agents (179). This data clearly shows that EP can be utilized not only to improve the delivery 
and expression of transgenes, but also as a reliable means of increasing immune responses 
against a broad panel of pathogens for which vaccines are in dire need. 
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Muscle has been the traditional target for vaccine delivery and therefore the early device 
production was aimed at manufacturing invasive EP electrodes that inserted deep into muscle 
tissue. The rationale for using it as a target was that it is highly vascularized, multinucleated 
and it has the ability to express transgenes at a high rate for extended periods of time (180, 
181). Skeletal muscle is also unique in immunological terms. It fits the definition of all 
immuno-privileged organs by having a slow turnover of cells which is instrumental for the 
survival of the individual and of the species (182, 183). Similar to other immuno-privileged 
sites, skeletal muscle in physiological conditions lacks APCs and has low levels of expression 
of MHC I and II molecules. However, unlike the classical immunologically privileged sites, it 
is rich in lymphatic vasculature and presents no physical barriers to the immune system. 
Inflammation in the skeletal muscles is often followed by activation of macrophages and 
accumulation of regulatory T cells, which favors tissue regeneration and limits autoimmunity 
(184). Accumulation of CD4+ and CD8+ lymphocytes has also been reported, mostly due to 
the persistent inflammation or immune-mediated damage (185). Altogether, this suggests that 
immune intervention at this site would prioritize tissue repair and timely termination of the 
inflammation process. One of the undesirable effects associated with IM EP delivery was the 
high degree of pain experienced by the recipients (186). Subsequently, alternative sites for 
delivery have been explored with skin emerging as a prime competitor. It is a very attractive 
target for vaccine delivery because of the fact that skin is rich in APCs and is very accessible. 
Recent studies have shown that expression of transgenes in skin benefits greatly from EP 
mediated delivery (187–189). There also are a wealth of data demonstrating the superiority of 
skin in inducing cellular immune responses after DNA immunization (190). 
Skin is the largest organ in the human body possessing a high degree on immunological 
complexity. It serves as a physical barrier, which deters the entry of external agents and also 
performs various regulatory functions such as temperature control, fluid balance and many 
others. The thickness of human skin ranges between 0.5mm at its thinnest (eyelids) to around 
4.0 mm on the soles of the feet and hands. Structurally is can be divided into epidermis, 
dermis, and a subcutaneous layer. The epidermal layer is composed of keratinocytes, which 
form the bulk of it, however, it also consists of dendritic cells known as Langerhans cells, 
resident CD8+ T cells and a proportion of melanocytes (191). Langerhans cells are the 
prevailing APCs of the epidermal layer and as such are very competent at taking up vaccine 
antigens, processing and presenting them to lymphocytes (192). Although they are not 
classified as APCs, keratinocytes are also highly important in the induction of immune 
responses since they can be a major source of immune modulators (193). The cells of the 
epidermis are constantly sloughed off with the average turnover time being 27 days (194). 
The dermis has a more complicated structure with a heterogenous cellular composition. This 
compartment is populated by multiple types of specialized immune cells such as DCs, NK 
cells and CD4+ Th cells (195). Thus, by administering an immunogen into the skin one could 
target multiple immune cell types and efficiently induce a potent multi-facetted immune 
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response. The innermost layer of the skin is the subcutaneous layer. It is composed of fatty 
and connective tissue with the main cell types being adipocytes, fibroblasts, and macrophages 
(196). The skin is another very popular target for gene electrotransfer. This is largely due to 
its cell composition, easy accessibility and similar to muscle tissue, its ability to release gene 
products into the blood stream. The therapeutic potential of gene electrotransfer in skin has 
been employed in a human trial focusing on treatment of skin cancer (102). Other studies 
have shown conflicting results – some providing strong evidence of its immunological 
superiority over skeletal muscle and others demonstrating no benefits or even disadvantages 
of using skin as a delivery target tissue for DNA immunogens (197, 198). 
1.7.7 Electrodes 
Electric field in the tissues is administered through application of the electrodes, a conductive 
device that translates the electric current from the generator (electroporator) into the tissues. 
In the dawn of EP, electrodes were manufactured for transfection of cell cultures, and 
represented two parallel plates being inserted in a suspension of cells. Later, cuvettes were 
developed which are still widely used. However, due to the inconvenience of fitting parts of 
animals into chambers, the first electrode designs for in vivo use featured metal plates 
(tweezers or calipers) or needles/needle arrays, which penetrated the tissues (199). Later, 
numerous variations in the design of electrodes were adapted to the type of transfected tissues 
and requested expression profile. This was valid also for the needle electrodes which come in 
multiple configurations (number and length of needles) depending on the target tissues. Such 
electrodes can be inserted to variable depths and often have insulated shafts to prevent the 
spread of electrical pulses in the neighboring tissues. The maximal electric field of these 
electrodes is at the tips of the needles and decreases in a distance-dependent manner (200). 
Uninsulated needles can deliver pulses over a wider area and are thus also suitable for surface 
electroporation. 
Several types of electrodes have been developed to deliver electrical pulses into the skin. 
They can be split in two categories: penetrating (PE) and non-penetrating (NPE). NPEs are 
available as plate, tweezers, and caliper electrodes. All of these modalities are available in 
both single and multiple conformations and are designed to improve the delivery and 
expression of DNA plasmids in skin (201, 202). PEs are typically available as needle array 
electrodes in different configurations. They can provide a range of electric fields between 50-
1800 V/cm, pulse length of 0.05 to 650 ms, and pulse number of 1 to 18. Many reports have 
recently shown the great efficiency with which PEs facilitate gene electrotransfer resulting in 
a high rate of expression. A number of PEs have been used to carry out immunization trials 
against various pathogens with data showing that they were able to enhance both humoral and 
cellular responses as compared to immunization with DNA without EP (203–205). However, 
recent efforts have switched focus to development of NPE due to the increased pain 
associated with PEs. Heller and colleagues have been successful in developing minimally 
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invasive multielectrode array (MEA) for skin EP and optimizing the EP protocol as to reduce 
the pain caused by strong electric fields (206). They achieved that by reducing the distance 
between the electrodes so that lower voltages can create the same electric attained by using 
higher voltage pulses. The resulting decrease of area was compensated for by the introduction 
of additional electrode pairs on the surface of the device. The MEA features 16 electrodes 
spaced out at a distance of 2mm in a 4 x 4 array configuration. To achieve an electric field of 
250 V/cm it used 50 V pulses as opposed to the 200 V pulses required by typical electrode 
with a 8 mm gap (206). Similar alternations of this approach have managed to further reduce 
the voltage required for efficient gene electrotransfer to as little as 15 V (199). 
1.8 OPTICAL IMAGING 
A variety of imaging methods has been established to look beyond the physical barrier of skin 
in vivo. Based on the classical X-ray imaging, computer X-ray computed tomography (CT) 
has been developed for the identification of anatomical features, where an image is acquired 
based on the capacity of different tissues to absorb X-rays. Magnetic resonance imaging 
(MRI) represents a different approach that exploits the magnetic properties of hydrogen 
atoms. In that scenario hydrogen atoms are being excited by radio waves and then the radio 
waves that they emit when reverting back to their original state are recorded and quantified. 
These are techniques that help us understand the anatomical characteristics of different 
organisms. If combined with contrast agents and alternative imaging modalities such as single 
photon emission computed tomography and positron emission tomography they can serve to 
monitor processes at the molecular level (207–209). 
The advances in genetic engineering have enabled scientists to design proteins emitting 
luminescent or fluorescent light, detectable by various optical devices. Optical imaging 
possesses some key advantages over other imaging methods. It has been developed to have a 
relatively high throughput, where multiple animals can be imaged simultaneously over a 
short period of time. Image acquisition, which is performed using a CCD camera is usually 
quite straightforward and does not require the attendance of a specialist thereby unlocking the 
technique for use by a wide variety of researchers. Optical imaging is very well suited for in 
vivo studies, where it can be applied for monitoring at the cellular level of the different 
processes such as biodistribution (210), gene expression (211), enzyme activity (212), 
inflammation (213), and tumor spread (214) at the cellular level. In the field of optical 
imaging bioluminescence imaging (BLI) holds several distinct advantages over modalities 
utilizing fluorescence. A key difference between these methods is the virtual lack of 
background luminescence signal in animal tissues. Luminescent light is produced in 
detectable levels only when the enzyme reacts with an exogenously provided substrate. 
Unlike luminescence, fluorescence works by excitation from a source different than the 
emitting subject. Hence, the excitation light can also impact other fluorescent molecules 
present in tissues and result in a high degree of auto fluorescence background, which would 
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obstruct the detection of reporters. Furthermore, the requirement of florescent proteins to be 
illuminated by an excitation source doubles the travel distance of fluorescent light in tissues, 
which increases its scattering and results in a lower signal/noise ratio. 
1.8.1 Bioluminescence imaging of luciferases 
Bioluminescence is a natural phenomenon exhibited by a range terrestrial and marine species 
for various behavioral reasons such as defense, camouflage, communication, etc. (215) The 
process of emitting bioluminescent light has been thoroughly studied and reproduced by 
researchers in vitro. It is a result of the reaction between luciferase and a substrate know as 
luciferin. When this interaction occurs in the presence of oxygen and ATP the outcome is the 
oxidation of the substrate with release of a byproduct – luminescent light. The extensive 
understanding of this process has facilitated its integration as an essential tool in biomedical 
research. 
In order to make BLI possible in vivo, a gene encoding a luminescent reporter protein must be 
introduced into the tissue to be imaged. Currently there exists a variety of ways to transfer 
transgenes in animal models, such as using viral or bacterial vectors, injection of cells, 
electroporation-mediated transfer of plasmid DNA, as well as inducible expression in animals 
transgenic for the gene of interest. To perform BLI in live animals the subjects are 
anesthetized and placed in a light-tight chamber equipped with a CCD camera. Before 
detection of luminescent photons begins a reference picture is taken under low illumination, 
after which the CCD captures photons in complete darkness and during various exposure 
times. The data are then analyzed on a computer running the quantification software. The 
anatomical location of the signal source can be pinpointed by producing an overlay from the 
greyscale reference picture and the pseudocolor intensity picture that results from detection of 
luminescent photons (Fig. 3).  
 
The localization of bioluminescence signal can be further improved by the use of 
complementary methods such as bioluminescence tomography (BLT). In that imaging 
modality the difference in light scattering and attenuation at different wavelengths are taken 
into account in order to determine the depth of origin of the bioluminescence signal. Due to 
Figure 3. Graphical representation of 
the IVIS Spectrum used for 
bioluminescence imaging (BLI) (259). 
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the wide emission range of the bioluminescence emitting enzymes (560-660 nm for 
luciferase) a series of planar acquisitions can be performed allowing the calculation of the 
depth of the source, based on the signal intensity and adjusted with the known tissue 
attenuation at the respective wavelength. This information is then combined with computed 
tomography data to form a complete three-dimensional (3D) model of the subject (216). 
Luciferases are at the core of the phenomenon of bioluminescence, making the process 
possible by their enzymatic properties. The luciferase from the firefly (Photinus pyralis) 
consists of a single polypeptide (217), which uses luciferin as a substrate for an oxidation 
reaction in the presence of ATP and oxygen to generate light (218): 
 
The reaction between luciferase and its substrate results in the production of oxyluciferin. It is 
an electrically excited form of luciferin, which upon the return to its ground state releases a 
single photon (219). In the presence of an excess of luciferin, magnesium, and ATP the 
photons released are proportional to the amount of luciferase (220). Providing luciferin to 
cells expressing luciferase will result in emission of luminescence peaking at around 560 nm. 
The gene for luciferase has been cloned and optimized for eukaryotic expression making it 
convenient to use in various animal models. Alternative forms of luciferase are also available 
from organisms such as the yellow click beetle (Pyrophorus plagiophthalamus). These 
luciferases have different emission spectra that can either be green- or red-shifted with light 
peaking at 543 nm and 618 nm, respectively.  
Another variation of luciferase can be isolated from the marine species Renilla. Unlike firefly 
luciferase, it uses a coelenterazine as a substrate. The reaction between luciferase and its 
substrate is independent of cellular sources of energy, so ATP is not required for the 
generation of photons (221).  
 
The process of oxidative decarboxylation of coelentaerazine by the luciferase results in the 
production of coelenteramide, carbon dioxide, and light peaking at 450 nm.  
Bacterial luciferase is yet another form of the enzyme available in nature. In luminescent 
bacteria the enzyme uses reduced flavin mononucleotide (FMNH2), fatty aldehydes, and 
oxygen to produce light that peaks at 490 nm.  
Luciferase + Luciferin + ATP + O2 
Mg
++
Luciferase-Luciferin + AMP + PPi
Luciferase-Luciferin + AMP + O2 Oxyluciferin + CO2 + AMP
Oxyluciferin Oxyluciferin + light
(1)
(2)
(3)
Coentelerazine Coentelerazine + CO2 + light
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Bacterial luciferases are encoded by the lux gene, which also codes for an enzyme responsible 
for the synthesis of the substrate. The lux operon consists of 5 genes (luxA-luxE) and has been 
expression-optimized in mammals. Its use is further facilitated by the fact that it retains 
significant enzymatic activity at 37°C (222).  
1.8.2 Bioluminescence optical imaging in vivo 
The amount of detectable luminescence in vivo is largely dependent on the optical properties 
of the tissues, through which it has to pass in order to reach the CCD. Absorption and 
scattering are the main parameters that affect passing light. Emission of light with wavelength 
less than 600 nm is heavily affected by mammalian tissues, whereas red light (wavelengths 
longer than 600 nm) is not influenced as much. The main factors responsible for absorption 
of light in tissues are hemoglobin and melanin with both of them absorbing blue and green 
wavelengths. It is therefore advisable to utilize luciferases producing red-shifted light when 
targeting deep tissues, so that signal loss is minimized (223). In such cases enzymes like the 
Renilla luciferase should be avoided as they produce little light over 600 nm. Firefly 
luciferase, however, has an emission spectrum with more than 30% of light that has 
wavelength longer than 600 nm (211).   
Up to date BLI has been successfully implemented in the study of the animal models of many 
human diseases. One of the first instances of the imaging of luminescent reporters was 
conducted using Salmonella typhimurium, which expressed the bacterial luciferase (224). The 
luminescent signal from expressing bacteria was detected in many organs of infected animals. 
After these pioneering studies showed significant success many other bacterial strains have 
been modified to allow the expression of the lux operon and their application in disease 
models (225). However, bacteria are only a fraction of the organisms that are amenable to 
similar engineering. Other types of infectious agents such as viruses and fungi were also 
successfully modified to carry, deliver and express the luciferase gene (226, 227). Very 
recent studies have demonstrated how respiratory syncytial virus expressing luciferase can be 
utilized in studying virus replication and burden in vivo. The authors reported that performing 
whole body BLI in mice provided data of virus titers that correlated well with ex vivo plaque 
assays and qRT-PCR. Moreover, the technique opened up possibilities to monitor in real time 
the reduction of viral titers and replication after vaccination (228). 
Another tremendous advance in the study of in vivo processes was the use of BLI to monitor 
cells labeled with luciferase and assess their population kinetics and gene expression (229). A 
vivid example of this method are tumor studies, which used tumor cells engineered to express 
luciferase and then transferred into animal models (230, 231). This powerful approach has 
been applied in many in vivo studies that have investigated the dynamics of tumor growth and 
FMH2 + O2 FMN + RCOOH + H2O + light
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regression aimed to assess the efficacy of various treatments including chemotherapy and 
prophylactic and therapeutic vaccination (232, 233). Using a similar methods gene expression 
has also been successfully imaged with transgenic animal models expressing luciferase under 
specific promoters (229). 
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2 AIMS 
The present work focused on the development of in vivo bioluminescence imaging (BLI) 
techniques to:  
• Improve the delivery and expression (localization, level) of plasmid-based DNA 
immunogens in order to enhance their immunogenic performance. 
• Determine how the route and site of DNA vaccine delivery influences its further 
expression and immunogenicity and if these effect(s) are similar for immunogens 
polarized to induce cellular versus humoral immune response. 
• Follow the development of immune response in vivo replacing the intermediate 
immune tests and defining new end-points to terminate the trials of ineffective/non-
immunogenic and promote the effective DNA vaccine candidates. 
• Evaluate the in vivo effector/lytic potential of immune responses to eliminate the 
reporter/immunogen co-expressing cells, and create surrogate challenge models for 
infections in small laboratory animals.  
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3 RESULTS AND DISCUSSION 
In this section of my thesis I will summarize and discuss the main findings of its four 
constituent papers. The data will not follow the chronological order of the papers, but will 
rather be presented in a logical progression consisting of four sections. The basic 
experimental setup used to acquire each set of data is summarized in Table 1. Please refer to 
the papers for any fine details that might be missing in this section. 
 
Table 1. Summary of mouse DNA immunization experiments 
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pVaxLuc 5 im • 2  x 1 0 NA
pVaxLuc 5 id • 2  x 1 0 NA
pVax1 5 im • 2  x 1 0 2  x 1 0
pVax1 5 id • 2  x 1 0 2  x 1 0
pVaxLuc 1 0 im • 1  x 2 0 NA
pVaxLuc 1 0 id • 1  x 2 0 NA
pVax1 1 0 im • 1  x 2 0 NA
pVax1 1 0 id • 1  x 2 0 NA
pVaxLuc 1 2 id • • 2  x 2 0 NA
pVaxLuc 1 2 id • • 2  x 2 0 NA
pVaxLuc 1 2 id • • 2  x 2 0 NA
pVaxLuc 1 2 id • • 2  x 2 0 NA
pVax1 1 2 id • • 2  x 2 0 NA
pVax1 1 2 id • • 2  x 2 0 NA
pVax1 1 2 id • • 2  x 2 0 NA
pVax1 1 2 id • • 2  x 2 0 NA
RTwt-opt-in 5 id • 2  x 1 0 2  x 1 0
pVax1 5 id • 2  x 1 0 2  x 1 0
RTwt-opt-in 5 id • • 2  x 1 0 2  x 1 0
pVax1 5 id • • 2  x 1 0 2  x 1 0
RTwt-opt-in 8 id • • 2  x 1 0 2  x 1 0
pVax1 8 id • • 2  x 1 0 2  x 1 0
RTwt-opt-in 5 id • 2  x 1 0 2  x 1 0
RTwt-opt-in 5 im • 2  x 1 0 2  x 1 0
PR_Bin 5 id • 2  x 1 0 2  x 1 0
PR_Bin 5 im • 2  x 1 0 2  x 1 0
pVax1 5 id • 2  x 1 0 2  x 1 0
pVax1 5 im • 2  x 1 0 2  x 1 0
RTwt-opt-in 5 id • • 2  x 1 0 2  x 1 0
PR_Ain 5 id • • 2  x 1 0 2  x 1 0
Paper II
Paper I
Paper III
Paper IV
  
32 
 
3.1 THE DELIVERY AND EXPRESSION OF DNA IMMUNOGENS DEPEND ON 
THE PARAMETERS OF ELECTROPORATION 
The method of delivery of DNA vaccines is one of the crucial determinants of their 
subsequent immunogenicity. Other factors, such as the choice of target of gene delivery, also 
play an instrumental role in shaping of the subsequent immune responses. To address these, 
we undertook the task to thoroughly investigate the effect of injection site and expression 
localization on the efficacy of genetic vaccines. We also sought to study additional aspects of 
the process of DNA transfer such as electroporation. EP greatly benefits transgene expression 
and largely predefines the outcome of DNA immunization. An optimal gene electrotransfer 
depends on the combination of four main parameters: voltage, current, pulse duration and 
pulse polarity. These intrinsic properties of the electrical pulses are relayed to an important 
EP instrument – the electrode.  
We evaluated the importance of the electrotransfer parameters by transfecting mouse skin or 
muscle with the luciferase (Luc) reporter gene and performing a longitudinal follow up of 
Luc expression by non-invasive BLI. Luminescence intensity is known to be directly 
proportional to the amount of expressed luciferase (234). Thus, by assessing 
bioluminescence, we can directly measure the level of protein expression. A plasmid, 
pVaxLuc encoding the firefly luciferase was introduced into BALB/c mice using different EP 
regimens. 
Most of the early work on delivery and imaging of Luc reporter genes was performed with a 
CELLECTIS DermaVax device, which is unfortunately limited in the selection of electrodes 
that it could utilize. Due to this we switched to the CUY21EditII pulse generator (BEX Ltd., 
Tokyo, Japan). Before proceeding with further testing, we compared the performance of the 
two devices equipped with different electrodes. Mice immunized with a single dose of 
expression optimized gene encoding HIV-1 reverse transcriptase (RT)/Luc, using either of 
devices resulted in similar level of production of IFN-γ/IL-2 response (Paper IV). These data 
confirmed that the CUY21EditII was as good as the DermaVax and therefore suitable further 
testing of the remaining variables in the EP process. 
A wide range of parameters had to be tested due to the lack of established protocols with 
specific recommendations for each electrode in different animal models. The process of 
optimization began with comparing electrodes, to choose ones serving for the highest in vivo 
transfection/gene expression levels. Most of our preclinical experience was founded on the 
use of the multineedle array electrode mounted on the DermaVax device. This electrode was 
adapted for small animal models by reducing the number of pins of the clinically approved 
version of the same electrode. However, there were alternative options available including 
some that were less and some that were more invasive. We tested plate (tweezer) electrodes, 
which do not penetrate the skin. These types of electrodes require the injection site on the 
skin to be pinched. Another prerequisite is a stronger electric field since the DNA suspension 
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is under the skin and the electrodes do not directly come into contact with it. This often 
results in considerable tissue damage and burns (190). We found this type of electrodes to be 
inferior to multineedle arrays. We also tested two-needle and fork-plate electrodes (Fig. 4A). 
The former are penetrating electrodes with insulated needles. It can be inserted to a depth up 
to 1 cm and delivers the electric pulses at the tips of the needles. Although EP administration 
was easier using this electrode, its performance was suboptimal compared to multineedle 
arrays. The last alternative we assessed was the fork-plate electrode. It provided reasonable 
expression levels that were comparable to those obtained by multineedle array EP, however, 
its application significantly increased the time required to administer the electric pulses. 
Next we addressed the effect of voltage (Fig. 4B). Earlier studies have suggested that 
voltages between 10 and 100 V are optimal for gene delivery in skin. Exceeding this limit 
could result in excessive tissue trauma and hamper the overall transfection rate (235). 
Particular emphasis has been placed on the utilization of low voltage pulses due to the 
decreased sensation of pain associated with the procedure. Some studies have shown that skin 
electroporation with <60 V pulses results in improved transgene expression (236). By 
delivery of either pVaxLuc (Luc DNA) or a mixture of Luc DNA with an optimized DNA 
immunogen based on HIV-1 RT (RT/Luc DNA) we studied how these parameters interact 
and contribute to cellular and humoral immune responses after EP-assisted immunization.   
Using a multineedle array electrode we compared early expression in mice injected with an 
RT/Luc mix at 15, 30, 50 and 100 V. Mice immunized with unipolar 15 V and 30 V pulses 
exhibited no or very poor reporter gene expression and 100 V EP resulted in higher 
luminescence levels as compared to 50 V (Paper IV). Contrary to previous studies we found 
that higher voltages generated better transfection without any adverse effects as the 
immunization sites did not show any permanent trauma.  
One of the features of the CUY21EditII device that set it apart from the DermaVax is the 
ability to generate bipolar electrical pulses. As a next step of the optimization process we 
included alternating polarity pulses in the testing conditions and compared these with the 
unipolar 50 V and 100 V pulses. The results confirmed previous data suggesting an enhanced 
level of expression when a higher electric field is applied (115). We observed an increased 
reporter expression on both day 1 and day 3 after EP (Fig. 4 C).  
Changing the duration of the electrical pulses also contributed significantly to increasing the 
expression. Efficient electrotransfer of genes requires two key events to occur – 
permeabilization and electrophoretic drag of DNA into the cell. In order for these events to 
take place there are certain conditions to be met concerning the duration of both 
permeabilizing and driving (electrophoretic) pulses. The poration pulses must be of high 
voltage and in the µs range. We have empirically established a good permeablizing protocol 
that consists of 400 V 50 µs pulses. The voltage of the driving pulses was also established to  
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Figure 4. (A) Comparison of fork-plate, multi-needle and two-needle electrodes in the 
capacity to promote the expression of luciferase reporter shortly after gene delivery. Levels 
of bioluminescence at the sites of injections on day 1 and 3. BALB/c mice were injected with 
20 µg Luc administered ID to the left and to the right sites from the back of the tail, and 
immediately after electroporated with CUY21EditII (BEX Ltd, Japan) device equipped with 
fork-plate, multi-needle or two-needle electrodes. Electroporation was started with a 
poration pulse of 400 V, followed by a train of eight 100 V pulses, each 10 ms long 
administered with 20 ms intervals. Parameters of driving pulses optimal for gene delivery by 
intradermal injections followed by electroporation, defined on the example of luciferase 
reporter; the effects of pulse: (B) voltage; (C) polarity, (D) duration. Electroporation was 
initiated with a poration pulse of 400 V of 0,05 ms, followed by a train of eight 50 V (B, C, D) 
or 100 V (B) pulses of the same (+/+; B, C, D) or opposing/alternating polarity (+/-; C, D) 
administered for 10 ms (Short pulses; B, C, D) or 50 ms (Long pulses; C, D) with 20 ms 
(Short pulses) or 950 ms (Long pulses) intervals. Data represent an average photon flux from 
all injections sites in the group (photons/sec/cm2/sr) + SD. *p<0,05, **p<0,01 (Mann-
Whitney test). 
be 100 V, however the pulse generator manufacturer’s recommendation of duration seemed 
to conflict with the voltage chosen by us. This is why we conducted a trial of optimization 
and compared 50 ms (recommended) and 10 ms pulses. The 50 ms pulses inflicted significant 
tissue damage leading to low expression rates and a ultimately premature experimental end-
point. By reducing the pulse duration to 10 ms we were able to increase reporter expression 
while simultaneously eliminating any visible tissue damage (Fig. 4D).  
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Our optimal EP-assisted immunization protocol consisted of ID injection with immediate 
application of 400 V poration pulses and 10 ms driving pulses with alternating polarity. By 
using the CUY21EditII we were also able to carefully control pre-pulse skin resistance and 
thus minimize tissue damage all while maintaining an adequate current. Importantly, non-EP 
assisted delivery was ineffective – it resulted in 100 to 1000 times lower Luc expression 
levels (104 – 105 without compared to 107 to 108 p/s with EP) (data not shown). 
Our previous results had suggested an implicit relationship between the efficiency of DNA 
transfer and other parameters affecting electroporation, such as the resistance of skin (237). 
We investigated how skin resistance influenced transgene expression by electroporating 
pVaxLuc into the skin of BALB/c mice and monitoring the expression of the gene using BLI 
(238).  
 
Figure 5. Dependence of expression of luciferase gene assessed as the total photon flux to the 
estimated pre-pulse and monitored skin resistance during electroporation (Derma Vax). 
Analysis of the monitored skin resistance and average photon flux data from pervious Luc 
gene injection experiments involving 232 injections (A); Variance of average flux from the 
injection sites four days after Luc gene injection followed by pre-pulse resistance controlled 
vs. uncontrolled electroporation (B); Correlation between total photon flux (photons/sec) and 
electroporation parameters 2 h after injection in mice receiving intramuscular (C) and 
intradermal (D) Luc gene injections. 
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Our analyses of the detected luminescence intensity, known to be directly proportional to the 
amount of expressed luciferase present, showed that skin resistance inversely correlated with 
the efficiency of in vivo transfection and subsequent protein expression (Fig. 5 A, C, D).  
In Paper I we showed that efficient transgene expression after injection of DNA required 
electroporation (DermaVax, multineedle electrodes) delivered in a controlled fashion with 
pre-pulse resistance value maintained below 3000 Ω and monitored resistance values not 
exceeding 1000 Ω. The validity of this approach was clearly demonstrated by an experiment 
we performed comparing the outcome of DNA electrotransfer of a luciferase reporter in 
terms of emitted luminescence after a controlled versus an uncontrolled delivery of 
electroporation (Fig. 5B). By using BLI we were able to acquire quick and reliable feedback 
of how different parameters of the EP process affected the delivery and expression of the Luc 
gene. A controlled electroporation resulted in a significantly tighter variance range of 
luminescence values as well as higher overall intensity after ID delivery of the gene.  
3.2 IMMUNOGEN EXPRESSION IS INFLUENCED BY THE ANATOMICAL 
TARGET OF DELIVERY 
In the process of optimization of EP we observed a wide variation in the immunogen 
expression after DNA delivery. This posed a question for the capacity of different tissues cell 
types to internalize and express the electrotransferred DNA immunogens. To address this, we 
transfected the luciferase gene into the skin or muscle tissues and followed the expression by 
BLI for 21 days. The reporter gene was delivered to the skin using the standard Mantoux 
method (239) from here on referred to as ID injection. The target site for delivery into muscle 
was the caudal thigh muscles proximal the base of the tail. These injections are referred to as 
IM. All injections were followed by electroporation (DermaVax, multineedle electrodes) in 
conditions earlier found to promote high gene expression and good immune response (240). 
Luc expression of injected/electroporated sites was followed by 2D and 3D imaging started 1 
hour after the delivery. 
Two hours after injection no differences were observed in the intensities of luminescence 
from the sites of injection in muscle or skin. To ascertain the precision of delivery we 
performed 3D bioluminescence tomography (BLT) and indeed, saw a difference in the depth 
at which luciferase was expressed. ID injections resulted in superficial localization of 
luciferase (~1mm), whereas the highest intensity of bioluminescence after IM injection came 
from deeper layers of tissue (>2mm) (Fig. 6). Twenty hours post injection the relative 
luminescence emitted by the muscle was significantly higher than that of the skin. Notably, 
muscle and intradermal injections were found to result in different luminescence kinetics. 
DNA transfected in the skin yielded a maximum antigen production by day 1, whereas in 
muscle the maximum was reached by day 3 post injection. There were no statistically 
significant differences in the levels of luminescence from day 6 to day 21 of the follow-up, 
however, the tendency of signal reduction was evident and much clearly pronounced in skin 
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than in muscle. These data demonstrate that in comparison to the superficial skin-targeting 
injection (ID), plasmid immunogen delivered via deep injection (IM) results in a more 
sustained protein expression, and also gives a later peak in the expression of the immunogen 
(241) (Fig. 5). 
 
Figure 6. Expression of reporter gene after IM (A) and ID (D) injection. Tissue from injected 
mice was excised and monitored for reporter activity. Mice receiving IM injections did not 
have any luciferase present in excised skin but showed ample signal in muscle tissue (B, C). 
The opposite was true after ID administration of the reporter gene (E, F). 
Further, we assessed the immune responses induced by ID and IM administration of the 
luciferase gene. ID immunization resulted in 3-times higher secretion of IFN-γ compared to 
IM. IL-2 secretion in response to stimulation with peptides encoding CD8+ T cell epitope was 
also found to be higher in splenocytes from mice receiving ID injections. However, no 
luciferase-specific antibodies were detected after ID administration of luciferase, while IM 
injection induced a weak anti-Luc IgG response (titer 50). These data show that the ID 
injection of a DNA immunogen (242) in skin results in a less durable antigen production, but 
yields more potent cellular immune responses as compared to the DNA being delivered into 
the muscle tissues. On the other hand, IM administration supports longer-lasting antigen 
production, which might play a role in the induction of humoral response to the encoded 
immunogen.   
We performed a similar experiment comparing the expression kinetics of luciferase co-
delivered with plasmids encoding model Th1 and Th2 immunogens. We choose two HIV-1 
clade B-based DNA immunogens of opposing Th-polarity: HIV-1 protease (PR), which 
induces potent cellular immune responses of Th1-type while generating no or very poor 
humoral immune response (243), and reverse transcriptase (RT), which as DNA immunogen 
induces a Th2-type of immune response characterized by high titer of IgG, induction of anti-
RT IgA and production of IL-4 and IL-10 (244). Plasmids encoding PR and RT were 
D E F
CBA
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delivered by ID and IM in a mixture with the Luc reporter and then the luminescence levels 
were monitored for 21 days (Paper III).  
 
Figure 7. In vivo volume registration by BLT. The volume of tissue expressing luciferase in 
mice immunized intradermally (A, B) or intramuscularly (C, D) with PR/Luc DNA (A, C) or 
RT/Luc DNA (B, D) with sequential imaging done 20-24 hours post injection (day 1) and by 
the experimental end-point (day 21) (as indicated by text boxed over the panels). 
Luminescence kinetics demonstrate no reduction in the volume of expressing tissues in either 
ID or IM PR/Luc DNA immunizations (E). On the contrary, a significant reduction in volume 
is registered by day 21 for RT/Luc expressing tissues, after ID, and to smaller extent, IM 
immunization (F). Images were acquired by combined 3D BLI and micro-CT on Spectrum CT 
with data analysis using Living Image 4.5 software . Statistical comparison was done using 
Mann Whitney U-test; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
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At the early time points, skin and muscle supported similar levels of reporter expression. 
Patterns of the reporter expression for PR/Luc and RT/Luc delivered IM and ID were similar 
up to day 3. Interestingly, we revealed that the delivery of Th2-polarized DNA immunogen 
HIV-1 RT, both via ID and IM routes, resulted in a much lower end-point luminescence 
levels and volume of expressing tissues than the delivery of the Th1-polarized one, such as 
HIV-1 PR. Also, the bioluminescent signal from the sites of RT expression decayed at a 
lower initial, but higher overall rate than the signal from the sites of expression of PR. This 
indicated that the kinetics and the magnitude of reporter expression depended not only on the 
site of gene immunogen/reporter delivery, but also on the nature of the delivered gene. 
Overall, the Th2-polarizing immunogens generated a more pronounced loss of reporter 
expression with “contraction” of expressing tissues, after both ID and IM administrations 
than the Th1-polarized ones (Fig. 7). 
3.3 THE SITE OF DNA VACCINE DELIVERY AND EXPRESSION INFLUENCES 
THE POTENCY BUT NOT THE TYPE OF IMMUNE RESPONSE 
Next we tested if monitoring of the reporter gene activity could be applied to follow not only 
the delivery, but also the subsequent immunogenic performance of different types of DNA 
immunogens (Paper III). For this, we conducted a series of experiments, which sought to 
uncover the effects of ID versus IM delivery on the expression and immunogenic 
performance of polarized DNA-immunogens known to stimulate either Th1-, or Th2-type 
immunity. Specifically, we immunized mice with HIV-1 PR as a model Th1- immunogen 
(243) and HIV-1 RT as a model Th2-type immunogen (238). The plasmids were delivered by 
either ID or IM injections with EP (DermaVax) and the accuracy of delivery was confirmed 
and followed by both planar and 3D in vivo BLI. Tissue targeting was confirmed by the 
differences we observed in the kinetics of expression, which was monitored via co-delivery 
of the target DNA immunogens with a plasmid encoding Luc. In ID deliveries of DNA 
immunogen/Luc, the reporter expression peaked early and steadily declined thereafter. On the 
contrary, IM delivery of DNA immunogen/Luc followed by EP led to a strong sustained 
reporter expression. These profiles corroborate our previous findings on the kinetics of Luc 
expression after ID and IM delivery of DNA encoding Luc alone (Paper I) and are consistent 
with the expression kinetics described earlier for intradermal and intramuscular DNA 
immunizations. 
Murine splenocytes were stimulated in vitro with peptides that we have shown to induce a 
multi-cytokine response, namely aa 1-15 and 75-84 of PR, and aa 465-476 and 528-543 of 
RT (Fig. 8 A-D). Splenocytes from the PR-immunized animals exhibited a different readout 
after ID and IM immunization. Being a Th1 antigen, PR immunization resulted in the potent 
stimulation of cellular immunity both when delivered ID and IM. However, ID delivery 
generated significantly stronger cellular responses manifested by the production of IFN-γ and 
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Figure 8. Immune recognition of the peptides representing CD4+ and CD8+ epitopes of 
PR (A, B) and RT (C, D) by FluoroSpot test assessing in vitro production of IFN-γ (A, C) 
and IL-2 (B, D) in mice immunized with the plasmid encoding inactivated PR of HIV-1 
HXB2 in pVax1 vector mixed with pVaxLuc (A, B); plasmid encoding inactivated RT of 
HIV-1 HXB2 in pVax1 vector mixed with pVaxLuc (C, D). Cytokine response to the 
immunodominant CTL epitope of Luc in PR/Luc, RT/Luc and control empty vector/Luc 
DNA immunized mice (CTRL) is presented everywhere for comparison. Antibody response 
was assessed in mice receiving PR and RT DNA by ID (skin) and IM (muscle) delivery. 
Titer of IgG against PR (E), IgG, IgG1 and IgG2a against RT (F), and the ratio of anti-RT 
IgG2a/IgG1 (G). Mice were immunized and their responses were assessed on experimental 
end-point at day 21. 
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IL-2. This difference was observed when cells were stimulated both with peptides 
representing PR aa 1-15, and aa 75-84. Interestingly, for mice immunized with RT/Luc DNA 
there was little difference in the cytokine production after ID and IM immunizations. Both ID 
and IM immunization induced IFN-γ and IL-2 response against the peptide representing RT 
aa 528-543, preferentially recognized by the murine CD4+ T cells. Cellular response to the 
peptide representing RT aa 465-476 and 528-543 were low and mainly constituted of CD4+ T 
cells. This reflected the nature of RT as Th2-type immunogen with preferential induction of T 
helper over CTL response. The data may also reflect the peculiarity of FluoroSpot tests to 
capture IL-2 in the cell culture fluid giving preference to the registration of reactivities of 
Th2-polarized CD4+ T cells, which depend not (exclusively) on IL-2, but also on retained IL-
4 (245). Apart from this, anti-RT and anti-PR immune responses induced by ID and IM 
administrations targeted the same CD4+ and CD8+ T cell epitopes. Cellular response to the 
immunodominant epitope of Luc was weak to insignificant after ID, as well as after IM 
delivery. 
As a Th1-polarized immunogen, PR induced a very weak antibody response with IgG titers 
less than 200 after ID, and no antibodies after IM immunization. In contrast, the Th2-
polarized RT induced a strong antibody response. After single DNA-immunization, the titer 
of anti-RT IgG reached 2.7±0.7 x 104 in IM, and three-times higher levels 6.3±0.8 x 104 in ID 
immunization (Fig. 8 E-G). To assess if the Th-bias of RT would be affected by the route of 
delivery, we assayed the abundance of anti-RT antibodies of IgG1 and IgG2a subclasses, and 
calculated the IgG2a/IgG1 ratio, considering IgG2a/IgG1 <1 as a tell-tale sign of an antigen 
inducing a Th2-type immune response (246, 247). ID immunization tended to give a stronger 
IgG1 compared to IgG2a response, whereas the levels of anti-RT IgG1 and IgG2a in mice 
receiving IM injections of RT/Luc DNA did not differ. Due to this, IM administration yielded 
an average IgG2a/IgG1 ratio of more than 1, higher than that after ID administrations, 
although the difference did not reach the level of significance.   
Thus, for HIV-1 PR, immunization by the ID route enhanced cellular response and induced a 
weak antibody response, and via the IM route, induced only cellular response. For HIV-1 RT, 
immunization via the ID route enhanced the antibody response and the degree of polarization, 
while the IM route gave the opposite effect. 
In conclusion, by both in vitro and in vivo bioluminescence-based assays we have 
demonstrated that ID delivery strongly increases the magnitude of the immune response 
induced by Th1-, and to lesser extent, by Th2-polarized DNA immunogens. ID delivery 
amplified the response against Th1 and Th2 immunogens in a similar way, enhancing the 
responses characteristic to each of the immunogen types, cellular for Th1-type  immunogens 
as HIV-1 PR, and antibody for Th2-polarized ones such as HIV-1 RT, while not altering the 
response polarization, or epitope hierarchy/dominance predefined by the protein structure. 
Using ID DNA immunization followed by EP we raised potent cellular and antibody 
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responses against HIV-1 enzymes capable of clearing the expressing cells from the sites of 
immunization. The magnitude of these responses and their effector capacity turn these 
immunogens into attractive components of therapeutic DNA vaccines against drug resistant 
HIV-1. 
3.4 REPORTER EXPRESSION AS A SURROGATE MARKER FOR ANTIGEN-
SPECIFIC IMMUNE RESPONSE 
The presence of only a single CD8+ T cell epitope on the luciferase protein (242) makes it 
perfectly suited for the assessment of immune responses with a method utilizing its 
bioluminescent nature such as BLI. To do this we performed correlation analyses 
incorporating the luminescence intensity values at different time points and attributes of 
immune response including levels of IFN-γ and IL-2 production by stimulated splenocytes in 
in vitro tests. Mice which received ID injections demonstrated a strong inverse correlation 
between the amount IFN-γ, IL-2 and the level of emitted luminescence. This relationship was 
evident as early as 3 days post injection and reappeared after 21 days. No correlation was 
discovered when mice received IM injections due to a low magnitude of specific immune 
response (data not shown).   
We further verified the potential of luciferase to serve as means to follow the kinetics of 
expression of co-delivered gene immunogens. We were able to correlate the decrease of 
luminescence with the immune response against the DNA immunogen of lytic CD8+ and/or 
lytic CD4+ T cells (243, 248, 249). However, it remained unclear how this would relate to the 
Th2-polarized immunogens, which induce only limited cellular responses. To find out, we 
examined the bioluminescence/immune response correlations for mice immunized with Luc 
reporter DNA together with a Th2-polarized (RT) in comparison to a Th1 immunogen (PR). 
We correlated bioluminescence loss with the cellular and antibody responses of mice DNA-
immunized with RT or PR via the ID route since it promoted a stronger overall immune 
response. Cellular responses were represented by the number of splenocytes producing IFN-
γ, IL-2 and both cytokines in response to in vitro stimulation with peptides capable of 
inducing secretion of multiple cytokines, and antibody responses, by the end-point titer of 
specific IgG. These responses were correlated to the loss of bioluminescent signal calculated 
as the fraction of maximum signal retained at the sites of RT/Luc and PR/Luc delivery 
starting from when we began to register the loss of the signal to the experimental end-point. 
The analysis revealed significant correlations between the loss of bioluminescence signal and 
IFN-γ and IL-2 secretion in PR-immunized mice in response to stimulation with peptides 
representing PR aa 1-15 and 71-84/75-84. A highly significant inverse correlation of the 
magnitude of luminescence with the frequency of T cells secreting IFN-γ in response to 
stimulation with peptides representing CTL epitope of PR aa 1-15 and 75-84 was observed 
starting from day 15. Similar and even stronger correlations were identified for IL-2 and dual 
IFN-γ/IL-2 response. On the contrary, in RT DNA-immunized mice, correlations of 
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bioluminescent signal with the number of cells secreting IFN-γ and IL-2 in vitro in response 
to stimulation with RT aa 465-476 and 528-543 (which induce a multi-cytokine response of 
CD4+ and CD8+ T cells) were not significant. Interestingly, however, a strong inverse 
correlation of bioluminescence was observed for IFN-γ response induced by the peptide 
representing aa 207-223, which contains a cluster of CD4+ and CD8+ T cell epitopes. In one 
of the experiments, mice received an RT DNA boost immunization one month after the first 
administration of RT/Luc DNA. These mice demonstrated a strong inverse correlation of 
bioluminescence with IL-2 response to RT aa 207-223 already on day 1 after the boost. Apart 
from this, for RT/Luc DNA immunized mice, we observed a strong inverse correlation of the 
reporter signal with the magnitude of the end-point RT-specific antibody response (r = -0.7;  
p = 0.0006). Interestingly, a direct relationship (r = 0.46) was found when antibody titers 
were correlated with luminescence signal levels on day 1, indicating that a high level of 
antigen expression early after gene delivery has a positive impact on the development of 
antibody responses. Of note, all correlations of anti-RT immune response with photon 
emission after day 15 were non-significant due to the extremely low residual level of 
bioluminescence observed at late time points. The loss of luminescence and antibody 
response against PR were not correlated (as the levels of antibodies were negligible). 
Altogether, we demonstrated that the loss of bioluminescence from the sites of co-delivery of 
the reporter with Th1-polarized DNA immunogen (as PR) is correlated to CTLs, and of the 
Th2-polarized DNA immunogen (as RT), to the antibody response and boostable RT-specific 
response of effector CD8+ and lytic CD4+ T cells, indicating that these responses are involved 
in the clearance of the immunogen/reporter co-expressing cells. Recently, there has been an 
increasing interest in a systems biology approach for modelling the immune system and the 
way it responds to various stimuli such as infection or vaccination (250, 251). These efforts 
have a significant impact on the development of therapies and vaccines for different diseases.  
As the kinetics of reporter clearance correlate extremely well with antibody responses for 
Th2, and with cellular responses for Th1 immunogens, they can be advanced as a surrogate in 
vivo biomarker of the induction of the effector immune response in gene immunization. 
Furthermore, correlations of bioluminescence loss with the cytokine production in response 
to immunodominant T helper cell and CTL epitopes can be useful for predicting the immune 
responses in DNA-immunizations done with a mixture of immunogen/reporter expressing 
plasmids and for the immunogens and/or in the species, for which the immunodominant 
epitopes to use in the assessment of immune response are not known. 
Our data demonstrates that the clearance of RT expressing cells is antibody dependent, 
indicating involvement of pathways, alternative to CD4+/CD8+-driven cellular cytotoxicity, 
possibly ADCC. Series of studies stress the role of ADCC activity in controlling 
experimental HIV/SIV infections (252, 253). Peptides derived from Pol polyprotein are 
common ADCC targets in HIV infection (254). In rhesus macaques the induction of ADCC-
promoting antibodies specific for CD4+-induced epitopes on the background of a balanced 
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CD4+ T cell response correlated with protection from SIV infection (252). Corroborating 
these findings, we show that the intradermal DNA immunization with HIV-1 RT induces a 
strong antibody response associated with close to complete clearance of RT/reporter co-
expressing cells from the sites of immunization. Furthermore, the antibody production is 
accompanied by a CD4+ T cell response against multiple epitopes within HIV RT, with the 
dominant epitope correlated to the in vivo clearance of RT/reporter expressing cells. The 
precise mechanism of immune clearance of RT-expressing cells needs to be further 
elucidated, but already at this stage, the lytic potential of the response points at the utility of 
this enzyme as a component of therapeutic HIV DNA vaccines. 
3.5 IN VIVO IMAGING IN ASSESSMENT OF THE EFFECTOR CAPACITY OF 
THE IMMUNE RESPONSE 
To evaluate the in vivo effector capacity of immune responses, we immunized mice with RT 
encoding plasmids, mixed 1:1 (w/w) with the plasmid encoding Luc. Bioluminescence from 
the injection sites was monitored by in vivo imaging on days 1, 3, 9, 15 and 21 post 
immunization. A statistically significant decrease of the bioluminescence levels was observed 
in mice receiving Luc mixed with expression optimized RT compared to empty vector. The 
loss became dramatic by day 15. When Luc DNA was administered with the expression-
optimized RT genes, bioluminescence signals decreased by 99% within two weeks, and 
99.9%, within three weeks of DNA delivery. The loss of luminescent signal coincided with 
the development of cellular and antibody response against RT confirming the correlation 
between the levels of luminescence and lytic/effector potential of the specific immune 
response.  
In paper III we provided evidence that the development of cellular and antibody immune 
response could be monitored by co-delivery of a Luc reporter gene and in vivo imaging of the 
bioluminescence kinetics. The study was based on a single injection with EP by multineedle 
array (DermaVax) of an optimized PR or RT immunogens. In paper IV we went on to 
further optimize the EP parameters thus improving immunogen expression. The next 
unaddressed question was whether we can achieve an enhancement of immune response by 
applying different immunization schemes, and if so, whether this could be observed by in 
vivo imaging. 
The application of prime-boost vaccination strategies has been shown induce substantially 
higher magnitude of cellular and humoral responses than those obtained after a single 
immunization. DNA priming is believed to provide multiple advantages such as (a) efficient 
generation of memory T cells that can later be boosted in a homologous or heterologous 
manner (255, 256), (b) induction of effector T cells with enhanced IFN-γ production profile 
(257) and (c) induction of broad T cells responses against multiple epitopes including sub-
dominant ones (257). The timing of the booster immunization plays an essential role in the 
enhancement of memory immune responses (258). In paper IV we used a set of expression-
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optimized inactivated RT-based DNA immunogens to prime mice and then deliver a 
homologous DNA boost four weeks later. Assessment of the immune responses of these 
animals three weeks after the boost showed a higher overall titer of RT specific IgG.  
In order to obtain in vivo evidence of boosting of the effector immune response and well as 
the proof that it can be monitored by in vivo imaging, we designed the experiment in which 
animals were first primed with RT DNA and electroporated using protocol optimized for 
BEX device with fork-plate electrodes. Priming was done with RT DNA immunogen alone 
(without adding Luc DNA). Booster immunization consisted of a mixture of RT DNA and 
Luc DNA in a 1:1 w/w ratio. This allowed us to monitor only the RT-specific recall 
responses as the animals had no prior exposure to Luc immunogen that has the capacity to 
contribute to the immune-mediated clearance of cell in which it is expressed (Paper I). 
Shortly after delivery of the plasmid mixture luminescence levels were indistinguishable from 
those observed in previous priming immunizations. However, by day nine we observed 
almost complete clearance of luminescence - an event normally registered two weeks after 
the single RT/Luc DNA co-injections. Both antibody and cellular RT-specific immune 
responses were found to significantly correlate with the drop of luminescence levels (Paper 
III and Paper IV). 
The experimental setup we developed, in which the co-delivered reporter gene serves as a 
surrogate marker gauging the functionality of the immune response can be applied to other 
microbial vaccine tests that lack a challenge model in small laboratory animals. Moreover, 
the “antigen challenge” approach can be applied to practically any vaccination scenario and 
allows to significantly minimize assessment risks linked to the challenge with pathogens, as 
well as to reduce the cost and time spent in assessing the vaccine efficacy. 
We used this technique to obtain the in vivo proof of boosting of anti-RT effector immune 
response. If functional, the boosted immune response should clear the immunogen/reporter-
co-expressing cells in mice boosted with the RT gene faster than in mice immunized for the 
first time. To find out if this was the case, mice were primed with the expression-optimized 
inactivated RT gene variants as described above, and four weeks later boosted with a 1:1 
(w/w) mixture of Luc with the RT gene variant used in priming. Loss of bioluminescence in 
mice primed with an RT gene, and boosted with a mixture of this RT and Luc genes was 
compared to that in mice receiving this mixture for the first time. A dramatic loss of 
bioluminescence was observed by day 9 after the boost, i.e. one week earlier than in mice 
immunized with RT/Luc mixture once (Fig. 9). This shift indicated a pre-existence of the RT-
specific effector immune response induced by priming and furthered by booster injections 
(Paper IV).  
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Figure 9. Antigen challenge model for testing effector immune responses. Mice were 
immunized with DNA encoding two variants of RT in a mixture with Luc or alone. Animals 
receiving the mix of genes were monitored by BLI until day 21. Three weeks after the prime 
all mice were boosted with a mix of RT/Luc DNA. Dotted lines represent luminescence 
kinetics after prime and solid lines – after boost immunization. Days after each immunization 
are shown on the x axis. Luminescence levels decreased significantly faster after mice were 
administered a DNA boost. Statistical significant difference between values after prime and 
boost immunizations are indicated by asterisks; *p < 0.05; **p < 0.01; ***p < 0.001; ****p 
< 0.0001 (Mann-Whitney test). 
We also performed an in vivo evaluation of the effector/lytic potential of the immune 
response induced by DNA immunization in the settings of tumor challenge. For this, we used 
a syngeneic breast adenocarcinoma cell line engineered to express firefly luciferase (4T1luc2, 
PerkinElmer) and tested if by immunization with Luc DNA we can protect BALB/c mice 
from developing solid tumors and metastatic lesions (Paper II). The animals were primed 
and boosted by ID injection of plasmids encoding Luc and then electroporated with 
multineedle electrodes using either DermaVax (100 V pulses) or the CUY21EditII (50 V or 
100 V pulses) EP devices. Two weeks after the boost, mice were challenged with a 
subcutaneous injection of 5.0 x 103 4T1luc2 cells. We had previously established that the 
ectopic implantation of these cells does not affect their growth rate of metastatic capacity, so 
we continued to monitor luminescence produced by the injected cells for 23 days as well as 
the residual luminescence from the sites of injection of Luc DNA. All mice that were 
immunized using 100 V pulses showed no increase of luminescence from the sites of 
implantation of tumor cells, and developed no solid tumors (which normally develop during 
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6-7 days post implantation). Nine days after implantation less than 15% of the initial signal 
was detectable from the implantation site in these animals. As we previously observed, 
electroporation using 50 V pulses yielded weaker Luc expression in the immunized animals. 
Overall, the resistance to tumor growth coincided with the IFN-γ response against the CD8+ T 
cell epitope of Luc. All animals immunized with non-coding vector DNA showed no 
production of IFN-γ and developed palpable tumors by day nine. 
5. CONCLUDING REMARKS 
DNA vaccines represent an attractive vaccination platform for many infectious diseases 
because of their safety, stability, and ease of manufacture. However, they fall behind in their 
immunogenic performance, especially when compared to that of live attenuated, recombinant 
protein or viral vector vaccines. Recent developments in techniques such as in vivo 
electroporation have improved the immunogenicity of DNA vaccines considerably. Further 
improvements in gene immunogen delivery are needed to increase the ability of DNA 
vaccines to induce potent immune responses. In this work we showed that the efficacy of 
DNA immunogens could be enhanced by improving the delivery including optimization of 
electroporation procedure and selection of an appropriate delivery route best fitting a given 
immunogen. Furthermore, we have developed a functional method relying on non-invasive 
bioluminescence imaging to assess the immunogenicity of prototype DNA vaccines in vivo. 
We described correlations of bioluminescence loss with the cytokine production in response 
to immunodominant T helper cell and CTL epitopes of viral proteins encoded by DNA 
immunogens. These observations can be useful to predict the immune responses in DNA 
immunizations done with novel DNA immunogens and/or in the species, where the 
immunodominant epitopes are yet unknown. Further, an experimental setup was developed, 
in which the co-delivered reporter gene serves as a surrogate marker gauging the functionality 
of the immune response. This approach can be applied to test vaccine candidates for microbes 
which lack a challenge model in small laboratory animals. The “antigen challenge” approach, 
applicable to practically any vaccination scenario, allows to significantly minimize 
assessment risks linked to the challenge with pathogens, as well as to reduce the cost and time 
spent in assessing the vaccine efficacy. These findings would help to upgrade the DNA 
vaccine modality to the levels acceptable for standard clinical applications and make it 
suitable for combating the major health problems of our time.  
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